History
Since implementation, industry disclosure requirements have evolved into the published document that it is today through UK regulation, instructions from the European Federation of Pharmaceutical Industry Associations (EFPIA), influences from the US, and decisions made by ABPI Board members.
- 1958 First ABPI Code of Practice for the Pharmaceutical Industry
- 1968 UK Medicines Act
- 2006 ABPI (UK) Code of Practice requires pharmaceutical companies to disclose their involvement with patient organisations including publishing a list of all patient organisations to which they provide financial support
- 2007 EFPIA Patient Organisation Code agreed to come into operation on 1 July 2008
- 2008 Revised ABPI Code of Practice
- 2010 US Healthcare Reform
- 2011 EFPIA updates Patient Organisation Code
- 2011 Revised ABPI Code of Practice required pharmaceutical companies to disclose monetary value of support with a value of £250 or more (threshold removed in 2012)
- 2012 The ABPI Code of Practice requires pharmaceutical companies to disclose payments to healthcare professionals in aggregate for the first time
- 2012 The ABPI Code of Practice requires pharmaceutical companies to disclose grants and donations made to healthcare organisations on a per activity basis
- 2013 US Sunshine Act established
- 2013 EFPIA Disclosure Code agreed in June 2013
- 2014 First US Sunshine Act report due
- 2014 Revised ABPI Code of Practice
- 2015 Revised ABPI Code of Practice
- 2016 Revised ABPI Code of Practice
- 2016 First EFPIA Disclosures Report 2016
- 2016 Disclosure UK goes live on 30 June
Last modified: 20 September 2023
Last reviewed: 20 September 2023